Pembrolizumab in Combination with Folfirinox for Treatment of Advanced Pancreatic Adenocarcinoma With MSI-H.
Eur J Case Rep Intern Med
; 11(10): 004767, 2024.
Article
in En
| MEDLINE
| ID: mdl-39372147
ABSTRACT
Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment. LEARNING POINTS Very few patients survive pancreatic cancer, especially metastatic disease. Our patient is doing very well after a few years.There is little evidence for concurrent use of chemotherapy and immunotherapy. Our patient received it and has had no new lesions, and there has been an improvement on imaging.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Eur J Case Rep Intern Med
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
Italy